HCV-infected solid organ donors, direct-acting antivirals and the current challenges.
Introduction: The introduction of direct-acting antiviral therapy has generated tremendous interest in transplanting organs from HCV-infected donors, an option which has the potential to lower waiting times for solid organ transplantation (including kidneys). Safe, effective and pangenotypic direct-acting antiviral agents are currently available.Areas covered: We have identified studies from PubMed, EMBASE, and the Cochrane database to review risks and benefits on solid organ transplantation from HCV exposed donors in uninfected recipients.Expert opinion: The transmission of HCV with transplantation from anti-HCV positive kidneys without viraemia is extremely uncommon whereas recent evidence (five clinical studies, n=94 patients) shows absence of HCV infection in HCV naïve recipients who received kidneys from HCV RNA positive donors and underwent early DAAs. The evidence regarding non-kidney solid organ transplantation from HCV infected donors is more limited. One report showed the occurrence of dialysis-dependent kidney failure due to glomerulonephritis induced by acute HCV after liver transplant from a NAT positive donor into an HCV-naïve recipient. Transplantation of kidneys and other solid organs from HCV viremic donors into uninfected recipients has the potential to become the standard of care resulting in lower waitlist mortality. Studies with appropriate size and follow-up are needed urgently to establish clinical practice guidelines on this topic.